Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers
Advanced Science · 2025-12 · 12 (46)
DOI: 10.1002/advs.202507451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 11.11.2025. Verfasst von Jie Zheng und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Neoplasms, Transcriptome, Single-Cell Analysis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Single‐cell expression quantitative trait loci data offer promising opportunities to inform immune‐related drug development in cancer. However, pleiotropy can complicate causal inference. We introduce MR‐DEG, a framework that integrates Mendelian randomization (MR) and differential expressed gene (DEG) to strengthen causal inference. Using eight conventional MR and colocalization methods, we estimated effects of 11 021 dynamic gene expression profiles during CD4+ T cell activation on the risk of six cancer types. This identified 1000 gene‐cancer pairs with putative effects ( https://www.omicsharbour.com/sc‐eqtl‐mr ). Of these 1000 pairs, 517 involved 205 unique genes that were differentially expressed in relevant cancer tissues based on single‐cell RNA‐sequencing data. Of these 517 pairs, 265 were classified as likely causal using the conventional MR methods. After applying MR‐DEG to the remaining 252 potentially pleiotropic pairs, an additional 89 were classified as likely causal. Sixty‐four and 391 of the 1000 original pairs exhibited time‐ and non‐time dependent effects on cancer risk, respectively. Integrating the 1000 gene‐cancer pairs of MR findings and clinical trial evidence, we identified 200 pairs corresponding to 33 unique genes that encode drug targets under clinical investigation. These results demonstrate how combining genetic, transcriptomic and clinical trial evidence can reduce pleiotropic bias, and prioritize immune‐related drug targets for cancer prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumour, Sha…
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
- Center for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada.
ORCID-Profile: Jie Zheng
Förderung
- National Key Research and Development Program of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support
- National Institute for Health Research Senior Investigator
- Cancer Research UK 25
- MRF_
- NIHR Bristol Biomedical Research Centre
Zitieren
APA
Zheng, J., Yang, Q., Liu, H., Zhao, H., Wang, S., Liu, Y., Wu, X., Ding, Y., Ying, H., Ye, Y., Huang, X., Ye, L., Zheng, R., Lin, H., Li, M., Wang, T., Zhao, Z., Xu, M., Duan, Y., …, & Bi, Y. (2025). Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers. Advanced Science, 12(46). https://doi.org/10.1002/advs.202507451
Vancouver
Zheng J, Yang Q, Liu H, Zhao H, Wang S, Liu Y, et al. Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers. Advanced Science. 2025;12(46). doi:10.1002/advs.202507451
BibTeX
@article{Zheng2025,
author = {Zheng, Jie and Yang, Qian and Liu, Haoyu and Zhao, Huiling and Wang, Shuangyuan and Liu, Yi and Wu, Xueyan and Ding, Yilan and Ying, Hui and Ye, Youqiu and Huang, Xi and Ye, Lei and Zheng, Ruizhi and Lin, Hong and Li, Mian and Wang, Tiange and Zhao, Zhiyun and Xu, Min and Duan, Yi and Guo, Hao and Yuan, Zhongshang and Haycock, Philip and Davey Smith, George and Martin, Richard M and Ning, Guang and Hu, Fang and Wang, Weiqing and Gaunt, Tom R and Lu, Jieli and Bi, Yufang},
title = {Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {46},
doi = {10.1002/advs.202507451}
}
EUVIMED